JP2023504445A5 - - Google Patents
Info
- Publication number
- JP2023504445A5 JP2023504445A5 JP2022532037A JP2022532037A JP2023504445A5 JP 2023504445 A5 JP2023504445 A5 JP 2023504445A5 JP 2022532037 A JP2022532037 A JP 2022532037A JP 2022532037 A JP2022532037 A JP 2022532037A JP 2023504445 A5 JP2023504445 A5 JP 2023504445A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- nhr
- compound according
- aryl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL2019000109 | 2019-11-27 | ||
| PLPCT/PL2019/000109 | 2019-11-27 | ||
| PCT/EP2020/083596 WO2021105334A1 (en) | 2019-11-27 | 2020-11-27 | Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504445A JP2023504445A (ja) | 2023-02-03 |
| JP2023504445A5 true JP2023504445A5 (https=) | 2023-12-05 |
| JP7852923B2 JP7852923B2 (ja) | 2026-04-28 |
Family
ID=69024572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022532037A Active JP7852923B2 (ja) | 2019-11-27 | 2020-11-27 | セレブロンに結合するピペリジン－２，６－ジオン誘導体、及びその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240343706A1 (https=) |
| EP (1) | EP4065571A1 (https=) |
| JP (1) | JP7852923B2 (https=) |
| KR (1) | KR20220106801A (https=) |
| CN (1) | CN115023419A (https=) |
| AU (1) | AU2020392427B2 (https=) |
| WO (1) | WO2021105334A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022255888A1 (en) * | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
| WO2024015340A1 (en) * | 2022-07-12 | 2024-01-18 | Regents Of The University Of Michigan | Cereblon ligands and uses thereof |
| EP4584259A1 (en) | 2022-09-09 | 2025-07-16 | Innovo Therapeutics, Inc. | Ck1alpha and dual ck1alpha / gspt1 degrading compounds |
| WO2024123195A1 (en) * | 2022-12-06 | 2024-06-13 | Captor Therapeutics S.A. | Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
| KR20250130610A (ko) * | 2022-12-06 | 2025-09-02 | 캡터 테라퓨틱스 에스.에이. | 유비퀴틴 리가제 및 표적 mcl-1 단백질에 결합하는 이작용성 화합물을 사용하는 표적화된 단백질 분해 |
| CN120530094A (zh) * | 2023-01-12 | 2025-08-22 | 田边三菱制药株式会社 | Cereblon E3连接酶结合化合物、包含其的药物组合物及其制造方法 |
| CN121843932A (zh) | 2023-08-31 | 2026-04-10 | 先正达农作物保护股份公司 | 杀有害生物活性吲唑化合物 |
| CN117224547B (zh) * | 2023-09-12 | 2025-05-27 | 中国医科大学附属第一医院 | 一种小分子化合物dBET1在银屑病治疗中的应用 |
| WO2025063888A1 (en) | 2023-09-19 | 2025-03-27 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| WO2008007979A1 (en) * | 2006-07-12 | 2008-01-17 | Auckland Uniservices Limited | (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives |
| CL2007002513A1 (es) | 2006-08-30 | 2008-04-04 | Celgene Corp Soc Organizada Ba | Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras. |
| ME02420B (me) | 2006-09-26 | 2016-09-20 | Celgene Corp | 5-supstituirani derivati kinazolinona kao sredstva protiv raka |
| EP2277869A1 (de) * | 2009-06-24 | 2011-01-26 | Bayer CropScience AG | Cycloalkylamidbenzoxa(thia)zole als Fungizide |
| PL3202460T3 (pl) | 2010-02-11 | 2019-12-31 | Celgene Corporation | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| BR112018068906A2 (pt) | 2016-03-16 | 2019-01-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| EP4467143B1 (en) | 2017-07-10 | 2026-03-11 | Celgene Corporation | Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile |
| CN118108706A (zh) * | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| IL302595A (en) | 2018-04-13 | 2023-07-01 | Arvinas Operations Inc | Servalon ligands and bifunctional compounds containing them |
| EP3814330A4 (en) | 2018-06-29 | 2022-07-20 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CA3154386A1 (en) * | 2019-10-17 | 2021-04-22 | Michael Berlin | Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety |
-
2020
- 2020-11-27 JP JP2022532037A patent/JP7852923B2/ja active Active
- 2020-11-27 AU AU2020392427A patent/AU2020392427B2/en active Active
- 2020-11-27 WO PCT/EP2020/083596 patent/WO2021105334A1/en not_active Ceased
- 2020-11-27 EP EP20811632.7A patent/EP4065571A1/en active Pending
- 2020-11-27 CN CN202080094725.5A patent/CN115023419A/zh active Pending
- 2020-11-27 KR KR1020227021713A patent/KR20220106801A/ko active Pending
- 2020-11-27 US US17/780,891 patent/US20240343706A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023504445A5 (https=) | ||
| JP2008509166A5 (https=) | ||
| JP2003531835A5 (https=) | ||
| JP2020073472A5 (https=) | ||
| JP2016153410A5 (https=) | ||
| JP2021073272A5 (https=) | ||
| JP2020134860A5 (https=) | ||
| JP2018524339A5 (https=) | ||
| JP2024542188A5 (https=) | ||
| JP2008510828A5 (https=) | ||
| JP2004517087A5 (https=) | ||
| JP2023535815A5 (https=) | ||
| JP2002536329A5 (https=) | ||
| JP2005504042A5 (https=) | ||
| JP2006143737A5 (https=) | ||
| JP2008503484A5 (https=) | ||
| RU2009118254A (ru) | Фенилацетамиды в качестве ингибиторов протеинкиназ | |
| TW200410960A (en) | Calcium receptor modulating agents | |
| JP2008509928A5 (https=) | ||
| JPWO2020004649A5 (https=) | ||
| JP2005530811A5 (https=) | ||
| JP2005508368A5 (https=) | ||
| SI20876B (sl) | Derivati propanojske kisline, ki inhibirajo vezavo integrinov na njihove receptorje | |
| JP2023538524A5 (https=) | ||
| JP2023504143A5 (https=) |